Sage Therapeutics Inc., of Cambridge, Mass., said it priced an underwritten public offering of 3.52 million shares of its common stock at $85.00 each. The gross proceeds are expected to be approximately $300 million. The company has also granted the underwriters a 30-day option to purchase up to an additional 529,411 shares of its common stock.